ArticleBMC public health2025
Global burden and trends of multiple myeloma attributable to high body mass index: a comprehensive analysis of the global burden of disease 2021 study with projections to 2040.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Body mass index and multiple myeloma: a systematic review and dose-response meta-analysis of prospective cohort studies.BMC cancer · 2026Pooled it
- RNA-Based Therapeutic Strategies in Multiple Myeloma: From Molecular Targets to Delivery and Clinical Translation.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity and overweight are increasingly recognized as significant risk factors for the incidence and progression of Multiple Myeloma (MM). However, its epidemiological investigation including the disease burden and its trends remains insufficiently explored.
objectiveThis study aims to examine the burden and temporal trends of MM attributable to high body mass index (BMI), focusing on variations by age, sex, Socio-demographic Index (SDI), and geographic region.
methodsData on MM cases linked to high BMI were obtained from the Global Burden of Disease (GBD) 2019 study, including deaths, disability-adjusted life-years (DALYs), and their age-standardized rates. Temporal trends in mortality were analyzed, and the relationships between SDI, standardized exposure value (SEV), and MM burden were assessed using Pearson correlation analysis.
resultsBetween 1990 and 2021, MM deaths due to high BMI increased from 3.00 thousand to 9.20 thousand, while DALYs rose from 72.00 thousand to 207.60 thousand. The age-standardized mortality rate (ASMR) and age-standardized DALY rate (ASDR) showed annual percentage increases of 0.91% and 0.94%, respectively. The highest burden was observed in high-SDI regions, though the most rapid growth occurred in lower-SDI areas. Western Europe and North America had the greatest disease burden, with males exhibiting consistently higher ASMR and ASDR than females. The oldest age groups (90-94 and 95 + years) were most affected. Strong positive correlations were found between MM burden and both SDI and SEV at regional and national levels. Future projections indicate a continued rise in deaths and DALYs by 2040.
conclusionThe growing impact of high BMI on MM, particularly in developed regions, highlights the need for targeted public health strategies to mitigate its effects. Increasing awareness and preventive measures are crucial to reducing the disease burden associated with high BMI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.